{"id":742724,"date":"2023-03-27T07:53:29","date_gmt":"2023-03-27T11:53:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxxinity-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-updates\/"},"modified":"2023-03-27T07:53:29","modified_gmt":"2023-03-27T11:53:29","slug":"vaxxinity-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxxinity-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-updates\/","title":{"rendered":"Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates"},"content":{"rendered":"
\n

CAPE CANAVERAL, Fla., March 27, 2023 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX<\/a>), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2022.<\/p>\n

\u201cWe are grateful for and proud of our accomplishments in our first full year as a public company, and remain on track to continue to hit our milestones in 2023 as we pursue our greater mission of democratizing health with our innovative vaccine technology,\u201d said Mei Mei Hu, CEO of Vaxxinity. \u201cThis year, we are poised to achieve our first potential marketing authorization as a company with UB-612, a heterologous booster vaccine candidate for COVID-19. We also expect to see two potential clinical proofs-of-concept in chronic disease in our migraine and hypercholesterolemia programs, and plan to complete Part B of our Phase 1 trial of UB-312 in Parkinson\u2019s disease. At our new headquarters in Cape Canaveral, we are utilizing our state-of-the-art laboratory capabilities to further expand our platform and pipeline.\u201d<\/p>\n

\n 2022 and Recent Clinical Pipeline Developments<\/strong>\n <\/p>\n

\n UB-311 in Alzheimer\u2019s disease (AD)<\/strong>\n <\/p>\n